AOP Orphan Pharmaceuticals AG
91/ II f / B4
23 articles with AOP Orphan Pharmaceuticals AG
10/15/2020Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
PharmaEssentia and AOP Orphan Receive Positive CHMP Opinion For Besremi™ (Ropeginterferon alfa-2b) For Treatment Of Polycythemia Vera (PV) In EU
PharmaEssentia today announced that the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Besremi, intended for the treatment of polycythaemia vera without symptomatic splenomegaly. The applicant for Besremi is AOP Orphan Pharmaceuticals AG (AOP Orphan).
AOP Orphan Announces Progress of its European Marketing Authorization Procedure of Ropeginterferon alfa-2b
AOP Orphan´s submission for marketing authorization of Ropeginterferon alfa-2b for treatment of Polycythemia Vera (PV) in the European Union (EU) has resumed after clock-stop. The conclusion of this centralized procedure is expected for Q4/2018.
AOP Orphan Pharmaceuticals AG And PharmaEssentiaAnnounce Latest Clinical Results For Ropeginterferon Alfa-2b In Polycythemia Vera From 3 Abstracts Presented At The 22nd Congress Of The European Hematology Association In Madrid
AOP Orphan Pharmaceuticals AG And PharmaEssentia Announce Pivotal Phase III Results For Ropeginterferon Alfa-2b In Polycythemia Vera At The American Society of Hematology Annual Meeting 2016
AOP Orphan Pharmaceuticals AG Announces European "Approvable" Opinion Of Its Ultra-Short Acting Beta Blocker Rapibloc (Landiolol)
AOP Orphan Pharmaceuticals AG Announces Launch Of Access Program For The World’s First Drug Against Lipodystrophy In HIV Patients, EGRIFTA, In Europe
AOP Orphan Pharmaceuticals AG Strengthens Core CNS Specialty Business With High Promise In Movement Disorder Treatments
AOP Orphan Pharmaceuticals AG Release: Innovative Antipsychotic ADASUVE To Benefit Even More Patients
AOP Orphan Pharmaceuticals AG Launches Lojuxta (Lomitapide) For Treatment Of Homozygous Familial Hypercholesterolaemia To The Austrian Market
Confluence Pharmaceuticals Signs Co-Development And Marketing Agreement With AOP Orphan Pharmaceuticals AG For Fragile X Syndrome Drug
AOP Orphan Pharmaceuticals AG Announces Progress Of Pivotal Phase 3 Trial PROUD-PV Applying Ropeginterferon ALFA 2B, A Novel, Long-Acting, Mono-Pegylated Interferon For Treatment Of Polycythemia Vera
Partnership Between AOP Orphan Pharmaceuticals AG and Ferrer Internacional: Joint Marketing of Adasuve® in CEE
AOP Orphan Pharmaceuticals AG Announces Progress of Pivotal Phase III Trial PROUD-PV of Novel Mono-Pegylated Interferon Alpha 2b for the Treatment of Polycythemia Vera
AOP Orphan Pharmaceuticals AG Spins Off Its Stake in Activartis Biotech GmbH and Outlines Business Strategy
AOP Orphan Pharmaceuticals AG Release: Essential Thrombocythemia (ET) – Convincing Data of ANAHYDRET Study Now Published
AOP Orphan Pharmaceuticals AG Reports Positive Phase II Data of Novel Mono-Pegylated Interferon Alpha 2b for Treatment of Polycythemia Vera (PV)